作者
Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, Francesco Buccisano, Christopher S Hourigan, Lok Lam Ngai, Jesse M Tettero, Costa Bachas, Constance Baer, Marie-Christine Béné, Veit Bücklein, Anna Czyz, Barbara Denys, Richard Dillon, Michaela Feuring-Buske, Monica L Guzman, Torsten Haferlach, Lina Han, Julia K Herzig, Jeffrey L Jorgensen, Wolfgang Kern, Marina Y Konopleva, Francis Lacombe, Marta Libura, Agata Majchrzak, Luca Maurillo, Yishai Ofran, Jan Philippe, Adriana Plesa, Claude Preudhomme, Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A van de Loosdrecht, Bert A van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter JM Valk, Brent L Wood, Roland B Walter, Christian Thiede, Konstanze Döhner, Gail J Roboz, Jacqueline Cloos
发表日期
2021/12/30
期刊
Blood, The Journal of the American Society of Hematology
卷号
138
期号
26
页码范围
2753-2767
出版商
American Society of Hematology
简介
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the …
学术搜索中的文章
M Heuser, SD Freeman, GJ Ossenkoppele… - Blood, The Journal of the American Society of …, 2021